Links to publications that use this kit in the last two years:
click here
Links to publications that use this kit:
Pyung-Hwan Kim, Minhyung Lee, Sung Wan Kim, Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model.
J Control Release. 2012 Aug 20;162(1):9-18. doi: 10.1016/j.jconrel.2012.06.010. Epub 2012 Jun 15.
Di pasquale G, Dicembrini I, Raimondi L, et al. Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes.
PLoS ONE. 2012;7(7):e40074.Nian Gong et al., Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity
Br J Pharmacol. 2011 May; 163(2): 399–412.
Wei Gao et al., Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats
J Pharmacol Exp Ther. 2011 March; 336(3): 881–890. doi: 10.1124/jpet.110.175752
Su Young Chaea, Cheng-Hao Jin et al., Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs
Journal of Controlled Release Volume 142, Issue 2, 3 March 2010, Pages 206–213
Kamei et al. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides.
J Control Release. 2009 Feb 27. [Epub ahead of print]
Samson et al. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model.
Mol Ther. 2008 Nov;16(11):1805-12.
